Literature DB >> 18512130

Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis.

M R Ananda-Rajah1, A Grigg, M A Slavin.   

Abstract

A man with acute lymphoblastic leukaemia developed disseminated Scedosporium prolificans infection following chemotherapy for disease relapse while on posaconazole prophylaxis. Scedosporium prolificans infection during posaconazole prophylaxis has not been reported previously. This report is timely as the uptake of posaconazole, the broadest spectrum azole clinically available, is likely to grow with recent evidence supporting its role as prophylaxis against invasive fungal infections in high-risk haematology patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512130     DOI: 10.1007/s11046-008-9131-2

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  21 in total

1.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

5.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  The significance of blood cultures positive for emerging saprophytic moulds in cancer patients.

Authors:  M S Lionakis; G P Bodey; J J Tarrand; I I Raad; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

7.  Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.

Authors:  Nina Singh; Ajit P Limaye; Graeme Forrest; Nasia Safdar; Patricia Muñoz; Kenneth Pursell; Sally Houston; Fernando Rosso; Jose G Montoya; Pamela Patton; Ramon Del Busto; Jose M Aguado; Robert A Fisher; Goran B Klintmalm; Rachel Miller; Marilyn M Wagener; Russell E Lewis; Dimitrios P Kontoyiannis; Shahid Husain
Journal:  Transplantation       Date:  2006-02-15       Impact factor: 4.939

8.  Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient.

Authors:  J Y Z Li; T Y Yong; D I Grove; P T H Coates
Journal:  Transpl Infect Dis       Date:  2007-04-11       Impact factor: 2.228

Review 9.  Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide.

Authors:  William J Steinbach; Wiley A Schell; Jackie L Miller; John R Perfect
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

10.  Infection with Scedosporium apiospermum and S. prolificans, Australia.

Authors:  Louise Cooley; Denis Spelman; Karin Thursky; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more
  5 in total

Review 1.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

2.  Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation.

Authors:  Joshua Wolf; Monica A Slavin
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

3.  Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review.

Authors:  Amaya Zabalza; Ana Gorosquieta; Encarnación Pérez Equiza; Eduardo Olavarria
Journal:  Ther Adv Hematol       Date:  2013-06

Review 4.  Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry
Journal:  Mycopathologia       Date:  2017-07-31       Impact factor: 2.574

5.  A Prospective, International Cohort Study of Invasive Mold Infections in Children.

Authors:  Rachel L Wattier; Christopher C Dvorak; Jill A Hoffman; Ava A Brozovich; Ibrahim Bin-Hussain; Andreas H Groll; Elio Castagnola; Katherine M Knapp; Theoklis E Zaoutis; Britt Gustafsson; Lillian Sung; David Berman; Natasha B Halasa; Mark J Abzug; Aristea Velegraki; Tanvi S Sharma; Brian T Fisher; William J Steinbach
Journal:  J Pediatric Infect Dis Soc       Date:  2014-07-16       Impact factor: 3.164

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.